Cargando…
Current concepts in SARS treatment
The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088022/ https://www.ncbi.nlm.nih.gov/pubmed/14991510 http://dx.doi.org/10.1007/s10156-003-0296-9 |
_version_ | 1783509454925332480 |
---|---|
author | Fujii, Takeshi Iwamoto, Aikichi Nakamura, Tetsuya Iwamoto, Aikichi |
author_facet | Fujii, Takeshi Iwamoto, Aikichi Nakamura, Tetsuya Iwamoto, Aikichi |
author_sort | Fujii, Takeshi |
collection | PubMed |
description | The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment of SARS is largely anecdotal, and so far no treatment consensus has been reached. We summarize 14 clinical reports and attempt to assess the effectiveness of various treatment regimens. A combination treatment of steroids and ribavirin was widely used empirically from the outset of the epidemic. In general, the use of steroids for SARS seemed beneficial, but the optimal timing, dosage, and duration of treatment have not yet been determined. On the other hand, ribavirin administration apparently reduced neither the rate of intratracheal intubation nor that of mortality. Moreover, significant toxicity, such as hemolytic anemia, has been attributed to ribavirin. A few preliminary trials and in vitro data suggest the possibility of treating SARS with interferon. Other agents, including the HIV protease inhibitor glycyrrhizin and convalescent plasma, remain to be evaluated. |
format | Online Article Text |
id | pubmed-7088022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70880222020-03-23 Current concepts in SARS treatment Fujii, Takeshi Iwamoto, Aikichi Nakamura, Tetsuya Iwamoto, Aikichi J Infect Chemother Article The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment of SARS is largely anecdotal, and so far no treatment consensus has been reached. We summarize 14 clinical reports and attempt to assess the effectiveness of various treatment regimens. A combination treatment of steroids and ribavirin was widely used empirically from the outset of the epidemic. In general, the use of steroids for SARS seemed beneficial, but the optimal timing, dosage, and duration of treatment have not yet been determined. On the other hand, ribavirin administration apparently reduced neither the rate of intratracheal intubation nor that of mortality. Moreover, significant toxicity, such as hemolytic anemia, has been attributed to ribavirin. A few preliminary trials and in vitro data suggest the possibility of treating SARS with interferon. Other agents, including the HIV protease inhibitor glycyrrhizin and convalescent plasma, remain to be evaluated. Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2004 2014-03-18 /pmc/articles/PMC7088022/ /pubmed/14991510 http://dx.doi.org/10.1007/s10156-003-0296-9 Text en Copyright © 2004 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Fujii, Takeshi Iwamoto, Aikichi Nakamura, Tetsuya Iwamoto, Aikichi Current concepts in SARS treatment |
title | Current concepts in SARS treatment |
title_full | Current concepts in SARS treatment |
title_fullStr | Current concepts in SARS treatment |
title_full_unstemmed | Current concepts in SARS treatment |
title_short | Current concepts in SARS treatment |
title_sort | current concepts in sars treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088022/ https://www.ncbi.nlm.nih.gov/pubmed/14991510 http://dx.doi.org/10.1007/s10156-003-0296-9 |
work_keys_str_mv | AT fujiitakeshi currentconceptsinsarstreatment AT iwamotoaikichi currentconceptsinsarstreatment AT nakamuratetsuya currentconceptsinsarstreatment AT iwamotoaikichi currentconceptsinsarstreatment |